Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine (VKA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03914053|
Recruitment Status : Completed
First Posted : April 12, 2019
Last Update Posted : April 12, 2019
|Condition or disease|
Despite the rise in prescriptions for direct oral anticoagulants, Vitamin K antagonists (VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.
The management of VKA in France seems hardly comparable to that of the neighboring countries in front of:
- A TTR estimated at 60%.
- Majority management of anticoagulant treatments by general practitioners.
- The weak development of clinics anticoagulants.
- The takeoff of direct oral anticoagulant prescriptions.
- Preponderance of fluindione prescriptions among the various oral anticoagulants.
It therefore seems interesting to study a cohort of French patients under VKA. Through the calculation of the TTR, the investigators will be able to draw a picture of the balance of the anticoagulant treatment and try to identify factors that can influence it.
|Study Type :||Observational|
|Actual Enrollment :||3387 participants|
|Official Title:||Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine : Study ok Variables Influencing the Time Paid in the Therapeutic Target|
|Actual Study Start Date :||July 1, 2017|
|Actual Primary Completion Date :||September 1, 2018|
|Actual Study Completion Date :||December 31, 2018|
- time spent in the therapeutic range (TTR) [ Time Frame: 1 day ]calculating their time spent in the therapeutic range (TTR).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03914053
|Montpellier, France, 34295|
|Principal Investigator:||Emile Emile||University Hospital, Montpellier|